menu search

NGENF / NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that its Chief Medical Officer, Dr. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held September 14-16 in London, UK. Dr. Mikol will present on NervGen's ongoing Phase 1b/2a study of NVG-291 in individuals with subacute or chronic spinal cord injury (SCI) during the SCOPE/Reeve Foundation/Spinal Research/Wings for Life co-sponsored pre-course on clinical trials on September 14 at 3:10pm BST. Read More
Posted: Sep 11 2023, 08:30
Author Name: Newsfile Corp
Views: 042055

NGENF News  

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

By Newsfile Corp
September 11, 2023

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a more_horizontal

NervGen Pharma to Present at Upcoming Investor Conferences

By Newsfile Corp
June 20, 2023

NervGen Pharma to Present at Upcoming Investor Conferences

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clini more_horizontal


Search within

Pages Search Results: